PMID- 21157036 OWN - NLM STAT- MEDLINE DCOM- 20110203 LR - 20211020 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 121 IP - 1 DP - 2011 Jan TI - Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. PG - 384-95 LID - 41495 [pii] LID - 10.1172/JCI41495 [doi] AB - Human leukemic stem cells, like other cancer stem cells, are hypothesized to be rare, capable of incomplete differentiation, and restricted to a phenotype associated with early hematopoietic progenitors or stem cells. However, recent work in other types of tumors has challenged the cancer stem cell model. Using a robust model of xenotransplantation based on NOD/SCID/IL2Rgammac-deficient mice, we confirmed that human leukemic stem cells, functionally defined by us as SCID leukemia-initiating cells (SL-ICs), are rare in acute myelogenous leukemia (AML). In contrast to previous results, SL-ICs were found among cells expressing lineage markers (i.e., among Lin+ cells), CD38, or CD45RA, all markers associated with normal committed progenitors. Remarkably, each engrafting fraction consistently recapitulated the original phenotypic diversity of the primary AML specimen and contained self-renewing leukemic stem cells, as demonstrated by secondary transplants. While SL-ICs were enriched in the Lin-CD38- fraction compared with the other fractions analyzed, SL-ICs in this fraction represented only one-third of all SL-ICs present in the unfractionated specimen. These results indicate that human AML stem cells are rare and enriched but not restricted to the phenotype associated with normal primitive hematopoietic cells. These results suggest a plasticity of the cancer stem cell phenotype that we believe has not been previously described. FAU - Sarry, Jean-Emmanuel AU - Sarry JE AD - Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. FAU - Murphy, Kathleen AU - Murphy K FAU - Perry, Robin AU - Perry R FAU - Sanchez, Patricia V AU - Sanchez PV FAU - Secreto, Anthony AU - Secreto A FAU - Keefer, Cathy AU - Keefer C FAU - Swider, Cezary R AU - Swider CR FAU - Strzelecki, Anne-Claire AU - Strzelecki AC FAU - Cavelier, Cindy AU - Cavelier C FAU - Recher, Christian AU - Recher C FAU - Mansat-De Mas, Veronique AU - Mansat-De Mas V FAU - Delabesse, Eric AU - Delabesse E FAU - Danet-Desnoyers, G AU - Danet-Desnoyers G FAU - Carroll, Martin AU - Carroll M LA - eng GR - K01 CA129151/CA/NCI NIH HHS/United States GR - K12CA07693/CA/NCI NIH HHS/United States GR - KO1-CA-129151-01/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20101213 PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (DNA Primers) RN - 0 (Il2rg protein, mouse) RN - 0 (Interleukin Receptor Common gamma Subunit) SB - IM MH - Animals MH - Base Sequence MH - Cell Differentiation MH - Cell Lineage MH - DNA Primers/genetics MH - Female MH - Hematopoietic Stem Cells/pathology MH - Humans MH - Immunophenotyping MH - Interleukin Receptor Common gamma Subunit/deficiency/genetics MH - Leukemia, Myeloid, Acute/genetics/*pathology/physiopathology MH - Male MH - Mice MH - Mice, Inbred NOD MH - Mice, Knockout MH - Mice, SCID MH - Models, Biological MH - Neoplastic Stem Cells/*pathology/physiology/*transplantation MH - Transplantation, Heterologous PMC - PMC3007135 EDAT- 2010/12/16 06:00 MHDA- 2011/02/04 06:00 PMCR- 2010/12/13 CRDT- 2010/12/16 06:00 PHST- 2009/10/19 00:00 [received] PHST- 2010/10/28 00:00 [accepted] PHST- 2010/12/16 06:00 [entrez] PHST- 2010/12/16 06:00 [pubmed] PHST- 2011/02/04 06:00 [medline] PHST- 2010/12/13 00:00 [pmc-release] AID - 41495 [pii] AID - 10.1172/JCI41495 [doi] PST - ppublish SO - J Clin Invest. 2011 Jan;121(1):384-95. doi: 10.1172/JCI41495. Epub 2010 Dec 13.